SCHEMBL5872051

SCHEMBL5872051

CCCCCCOC(=O)C(=Cc1cc[c]cc1)C(=O)OCCCCCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
TSHR P16473 5/20 0.48
LMNA P02545 4/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPT P10636 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPK1 P28482 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
S1PR4 O95977 1/20 0.46
S1PR1 P21453 1/20 0.46
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871779 0.99 MEN1 (0.50) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL5871410 0.94 MEN1 (0.51) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL5871929 0.88 KMT2A (0.54) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL11800607 0.84 LMNA (0.50) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL11504103 0.82 DNM1 (0.41) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL10898426 0.82 KMT2A (0.59) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL27278318 0.82 KMT2A (0.59) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL10898416 0.82 KMT2A (0.59) MEN1KMT2ATSHRLMNAALDH1A1
SCHEMBL5872078 0.82 MEN1 (0.72) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL5871984 0.81 TSHR (0.41) MEN1KMT2ATSHRLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 MEN1 3746/4885KMT2A 4290/4885TSHR 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.